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A physician who fails to enter the body of a patient  
with the lamp of knowledge and understanding  
can never treat diseases.  
He should first study all the factors,  
including environment,  
which influence a patient's disease, 
and then prescribe treatment.  
It is more important to prevent the occurrence of disease  
than to seek a cure. 
 
(Charaka Samhita, 1000 B.C.) 
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PREFACE 
 
In April 2011, I heard for the first time Professor Giorgio Zauli talking about TNF-
related apoptosis-inducing ligand (TRAIL) during his lecture at the final 
examination of the PhD students in Reproductive Sciences and Development 
at the University of Trieste. While listening that the administration of 
recombinant TRAIL ameliorated the severity of streptozocin-induced type 1 
diabetes in mice, I was captured by this potential new therapeutic chance for 
diabetes in children. 
One and a half year later, I had the great opportunity to start this PhD 
programme that allowed me to study TRAIL in 3 paediatric cohorts with type 1 
diabetes, from Naples to Cambridge passing through Trieste, and which is now 
coming to an end. 
The aim of the project was to define the values of circulating levels of TRAIL at 
the onset and during the progression of type 1 diabetes in affected children, 
because – in spite of all data in animal or in human cell models – no studies 
had yet fully investigated TRAIL levels in children with type 1 diabetes. 
The research was performed under the supervision of professor Alessandro 
Ventura (University of Trieste) and was in part supported by a grant from Italian 
Ministry of Health (Bando 2010 Giovani Ricercatori, code GR-2010-2310832). 
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ABBREVIATIONS	
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T2D   type 2 diabetes  
TIMP-1  tissue inhibitor of metalloproteinase-1 
TNF   tumour necrosis factor 
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TRAF   TNF receptor-associated factor-2 
TRAIL   tumour necrosis factor-related apoptosis-inducing ligand 
Treg  T regulatory 
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ABSTRACT 
 
Experimental evidence in animal models suggests that TNF-related apoptosis-
inducing ligand (TRAIL), a member of the TNF superfamily, might play an 
important role in type 1 diabetes (T1D). No studies had fully evaluated TRAIL 
levels in children affected by T1D. 
 
Study I – What happens to TRAIL levels in children with T1D? 
Retrospective study on 507 pediatric subjects consisting of patients diagnosed 
with T1D at onset (n = 167) or at later time points after diagnosis (n = 220), 
healthy individuals (n = 98, considered as controls), and healthy subjects 
positive to autoantibodies against β-cells	(n = 22).  
 
Study II – What happens to TRAIL levels at T1D onset and/or during diabetic 
ketoacidosis (DKA)? And what thereafter? 
Prospective study on a cohort of 11 pediatric subjects admitted for T1D onset 
or secondary DKA at the Emergency Department. A total of 80 blood samples 
were collected at admission (serial samples until stabilization), before hospital 
discharge and every 6 months during the clinical follow-up up to 18 months.  
 
Study III – What happens to TRAIL levels in long-standing T1D? Are TRAIL 
levels correlated with markers of residual β-cell mass, inflammation or 
autoimmunity? 
Retrospective cohort study on 232 young people with long-standing T1D 
(median 5.5 years); 219 patients had 2 available stored non-fasting serum 
samples collected (median time interval between visits 1.2 years), with a total 
of 451 samples available. 
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Conclusions 
1. TRAIL in type 1 diabetes 
- TRAIL levels are significantly reduced  in children with T1D compared to 
unaffected individuals 
- a significant seasonal pattern of TRAIL was observed (with the lower 
levels during summer and higher during spring) which may have some 
impact on the seasonal variation in the initial presentation of T1D 
 
2. TRAIL and autoimmunity 
- there are no differences in TRAIL levels between healthy subjects 
positive to autoantibodies against β-cells	and controls 
- there are no differences in TRAIL levels between T1D patients with and 
without islet-specific autoantibodies 
- there are no differences in TRAIL levels between T1D patients with or 
without other concomitant autoimmune diseases 
- TRAIL levels are associated with sCD25 (IL-2RA), a known biomarker 
for immune activation, in long-standing T1D, both as single values and 
as changes over time 
 
3. TRAIL at the onset of type 1 diabetes  
- the lowest levels of TRAIL are observed in patients at the onset of 
disease 
- among T1D patients at onset, the lowest levels of TRAIL are observed 
in patients with DKA  
- a worst metabolic status (documented by HCO3, BE, pH and CO2) is 
associated with lower TRAIL levels 
- TRAIL levels increase rapidly after short-standing insulin treatment has 
been established during the first hours after T1D onset and/or DKA  
- there is no association between TRAIL and C-peptide or A1c or insulin 
daily requirement at T1D onset 
 
4. TRAIL in long-lasting type 1 diabetes  
- reduction in TRAIL levels with respect to healthy controls persisted also 
in patients analyzed >1 year from diagnosis 
- TRAIL levels significantly increase from hospital discharge to the 6-
month follow-up, and then maintain without significant modulations up to 
18 months after onset 
- the levels of TRAIL negatively correlate with the insulin requirement up 
to 21 months of follow-up 
- TRAIL levels decrease with T1D duration in long-standing disease 
- there is no association between TRAIL and C-peptide or CRP in long-
lasting T1D 
 
Key words: TRAIL – type 1 diabetes mellitus - ketoacidosis – autoimmunity – 
insulin requirement – metabolic status – sCD25  
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RIASSUNTO IN LINGUA ITALIANA 
 
Evidenze sperimentali in modelli animali suggeriscono che il TNF-related 
apoptosis-inducing ligand (TRAIL), un membro della superfamiglia TNF, può 
giocare un ruolo importante nel diabete di tipo 1 (T1D). Nessuno studio aveva 
indagato in maniera approfondita i livelli di TRAIL nei bambini affetti da T1D.  
 
Studio I – Cosa succede ai livelli di TRAIL nei bambini con T1D? 
Studio retrospettivo su 507 soggetti pediatrici, consistenti in pazienti 
diagnosticati con T1D all’esordio (n = 167) o in un momento successivo dopo 
la diagnosi (n = 220), individui sani (n = 98, considerati come controlli), e 
soggetti sani positivi agli anticorpi diretti contro le β-cellule (n = 22).  
 
Studio II – Cosa succede ai livelli di TRAIL all’esordio di T1D e/o durante la 
chetoacidosi diabetica (DKA)? E cosa accade dopo? 
Studio prospettico su una coorte di 11 soggetti pediatrici ricoverati per esordio 
di T1D o DKA secondaria presso il Pronto Soccorso. Un totale di 80 campioni 
di sangue sono stati raccolti al momento del ricovero (campioni seriali fino alla 
stabilizzazione), prima della dimissione e ogni 6 mesi durante il follow-up clinico 
fino a 18 mesi. 
 
Studio III – Cosa succede ai livelli di TRAIL nel T1D di lunga durata? I valori di 
TRAIL sono correlati con marker di massa β-cellulare residua, infiammazione 
o autoimmunità? 
Studio retrospettivo di coorte su 232 giovani soggetti con T1D di lunga durata 
(mediana 5,5 anni); 219 pazienti avevano 2 campioni di siero disponibili, raccolti 
non a digiuno (mediana del tempo intercorso: 1,2 anni), per un totale di 438 
campioni disponibili.  
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Conclusioni 
1. TRAIL nel diabete di tipo 1 
- i livelli di TRAIL sono significativamente ridotti nei bambini con T1D 
rispetto ai soggetti non affetti 
- è stato riscontrato un significativo pattern stagionale di TRAIL (con i 
valori più bassi durante l’estate e i più alti durante la primavera) che 
potrebbe avere un impatto sulle variazioni stagionali nella presentazione 
iniziale del T1D  
 
2. TRAIL e autoimmunità 
- non ci sono differenze nei livelli di TRAIL tra soggetti sani con anticorpi 
diretti contro le β-cellule e i controlli 
- non ci sono differenze nei livelli di TRAIL tra i pazienti con T1D con o 
senza gli anticorpi diretti contro le β-cellule 
- non ci sono differenze nei livelli di TRAIL tra i pazienti con T1D con o 
senza altre malattie autoimmuni concomitanti 
- i livelli di TRAIL sono associati con sCD25 (IL-2RA), un noto biomarker 
di attivazione immune, nel T1D di lunga durata, sia come singola 
determinazione che come modifica nel tempo 
 
3. TRAIL all’esordio del diabete di tipo 1 
- i valori più bassi di TRAIL sono osservati nei pazienti all’esordio di 
malattia 
- tra i pazienti con T1D all’esordio, i valori più bassi di TRAIL si osservano 
nei pazienti con DKA 
- uno status metabolico peggiore (documentato da HCO3, BE, pH e CO2) 
è associato con valori più bassi di TRAIL 
- i livelli di TRAIL aumentano rapidamente subito dopo l’avvio di terapia 
insulinica nelle prime ore dopo l’esordio del T1D e/o la DKA 
- non c’è associazione fra TRAIL e il C-peptide o l’HbA1c o fabbisogno 
insulinico all’esordio del T1D 
 
4. TRAIL nel diabete di tipo 1 di lunga durata  
- la riduzione nei livelli di TRAIL rispetto ai controlli sani persiste anche nei 
pazienti analizzati dopo 1 anno dalla diagnosi 
- i livelli di TRAIL aumentano significativamente dalla dimissione 
dall’ospedale al follow-up 6 mesi dopo; dopo rimangono stabili senza 
modulazioni significative fino a 18 mesi dopo l’esordio 
- i livelli di TRAIL correlano negativamente con il fabbisogno insulinico fino 
a 21 mesi di follow-up 
- i livelli di TRAIL si riducono col tempo nel T1D di lunga durata 
- non c’è associazione fra TRAIL e il C-peptide o la PCR nel T1D di lunga 
durata 
Parole chiave: TRAIL – diabete mellito di tipo 1 - chetoacidosi – autoimmunità 
– fabbisogno insulinico – stato metabolico – sCD25  
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CHAPTER 1 
GENERAL INTRODUCTION 
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1. THE LONG HISTORY OF DIABETES MELLITUS 
 
The story of diabetes mellitus is a remarkable chronicle covering more than 
3,500 years of medical history1. 
A disease characterised by the “too great emptying of urine” finds its place in 
antiquity through Egyptian manuscripts dating back to 1500 B.C. Indian 
physicians called it madhu-meha (“honey urine”) because it attracted ants. The 
ancient Indian physicians Sushruta and Charaka were able to identify the two 
types, later to be named type 1 and type 2 diabetes2. 
The term diabetes (“siphon” in Greek) was introduced by Aretaeus of 
Cappadocia (81-138 A.D.): “diabetes is a wonderful affection, not very frequent 
among men, being a melting down of the flesh and limbs into urine...”. It was in 
1675 that Thomas Willis added the word mellitus ( “sweet like honey” in Latin) 
because of the taste of the urine. However, the anatomical localization and the 
metabolic alteration causing diabetes remained a mystery: in the 18th century 
Morgagni (1761) wrote that diabetes was a fatal disease, the location of which 
was impossible to establish. 
The relationship between diabetes and the pancreas was first clearly 
demonstrated by von Mering and Minkowski (1889)3, and Hedon (1893) 
completed the postulate of an internal secretion by demonstrating that pancreas 
transplantation to pancreatomized dogs prevented the development of 
diabetes. The origin of a pancreatic factor that controlled glucose homeostasis 
remained to be determined.  
Following the discovery of the pancreatic islet by Langerhans in 1869, 
Laguesse (1893) suggested that the pancreatic islets were a possible source 
of an internal secretion. A likely connection to diabetes was evidenced by 
Dieckhoff’s observations in 1894 that the pancreas of diabetic patients had a 
greatly diminished number of pancreatic islets4. 
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Technical advancements, particularly in techniques of microscopy and 
histology, allowed Lane (1907) and Bensley (1911) to describe the pancreatic 
α- and β-cells, and De Mayer (1909) proposed insulin as the factor from the 
pancreatic islets that controlled blood sugar. A search for insulin was 
undertaken by many workers but was greatly hindered by the extensive 
proteolytic activity in pancreatic extracts and the specific requirements to 
solubilise insulin.  
It was not until 1921 that Banting and Best successfully prepared pancreatic 
extract containing sufficient amounts of biologically active insulin5.  
The discovery of insulin had a dramatic effect on the therapy of diabetes: it was 
now possible to keep patients alive. Treatment during the period preceding the 
discovery of insulin was characterized by a starvation diet or undernutrition, 
with the patients allowed to receive very few calories each day. Before 1922 
the life expectancy of a child or young adult with diabetes was 1 year from 
diagnosis. By 1924, the life expectancy had risen to 7 to 8 years, and it 
improved rapidly with increased knowledge of insulin action and better training 
of physicians and nurses. Insulin had a marked social impact; it was long 
thought to be the cure for diabetes. However, almost 100 years of insulin 
therapy have proved the hormone only maintains survival in a chronic disorder 
associated with a risk of death that is twice as high as controls even in presence 
of a very good glycaemic control6. 
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2.	TYPE	1	DIABETES	MELLITUS	
 
Diabetes mellitus refers to a condition of hyperglycaemia that can be further 
classified into type 1, primarily due to a lack of insulin, or type 2, primarily due 
to peripheral insulin resistance.  
Type 1 diabetes (T1D) is one of the most common endocrine and metabolic 
conditions in childhood, showing an increasing incidence rate of about 3% 
per year during the last two decades. During the period 1990–2003 the 
incidence rate in Italy was 12.26 per 100,000 person-years, with an increasing 
temporal trend of 2.94% per year7. Maintaining this trend, a doubling of new 
cases of T1D in children is expected between 2005 and 2020, with increasing 
burden for the families and the health care system8. 
T1D is generally thought to be precipitated by an immune-associated, if not 
directly immune-mediated, destruction of insulin-producing pancreatic β-
cells9.  
The concept that T1D pathogenesis is immune-mediated is half a century 
old, dating back to the Sixties, when Burnet and Mackay included T1D among 
other autoimmune diseases (“a condition in which structural or functional 
damage is produced by the action of immunologically competent cells or 
antibodies against normal components of the body” arising by “the emergence 
of forbidden clones of T lymphocytes”)10. Two years later, Gepts found that 
insulitis was the key pancreatic morphological feature in recent-onset T1D and 
this led him to suggest that the immune system is involved in the pathogenesis 
of the disease11. Then, in 1974 Nerup demonstrated that T1D is a cell-mediated 
autoimmune disease by incubating peripheral blood mononuclear cells of 
diabetic patients with porcine islets material12. 
In terms of potential pathogenic mechanisms, CD8+ T cells are the most 
predominant population within the insulitis lesion, followed by (in declining 
order) macrophages (CD68+), CD4+ T cells, B lymphocytes (CD20+), and 
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plasma cells (CD138+)13. Surprisingly, FOXP3+ cells (i.e., regulatory T cells) 
and natural killer (NK) cells are rare in this lesion.  
A key distinguishing feature of T1D is the presence of autoantibodies against 
β-cell autoantigens. More than 90% of individuals with newly diagnosed T1D 
have one or more of the following autoantibodies at disease onset14: those 
reactive to islet cell (ICA), insulin (IAA), glutamic acid decarboxylase (GADA), 
insulinoma-associated autoantigen 2 (IA2A), and zinc transporter 8 (ZnT8A)15. 
These autoantibodies can appear as early as 6 months of age, with a peak 
incidence before 2 years of age in genetically susceptible individuals16; thus, 
they are present months to years before symptomatic onset. In addition to 
having diagnostic value in T1D, autoantibodies can help identify people with 
an increased risk for developing the disease, through detection in first-
degree relatives or in the general population. IAA concentration correlates with 
the rate of progression to overt type 1 diabetes in children followed from 
birth17,18. This finding, combined with an extensive series of independent 
investigations in humans and in rodent models of T1D, support the growing 
notion that proinsulin is a key autoantigen in the disease19, a concept that might 
partly explain the selective β-cell loss in T1D. 
Another supportive evidence for the autoimmune pathogenesis of T1D comes 
from the susceptibility of these individuals to other autoimmune conditions, 
including Hashimoto’s thyroiditis, Graves’ disease, Addison’s disease, coeliac 
disease, myasthenia gravis, and vitiligo20–23. 
Inflammation might contribute to early induction and amplification of the 
immune assault against pancreatic β-cells and, at later stages, to the 
stabilization and maintenance of insulitis. Inflammatory mediators probably 
contribute to the suppression of β-cell function and subsequent apoptosis; they 
may also inhibit or stimulate β-cell regeneration and might cause peripheral 
insulin resistance. The different effects of inflammation take place in different 
phases of the course of T1D, and should be considered in the context of a 
'dialog' between invading immune cells and the target β-cells. This dialog is 
	
19 
mediated both by cytokines and chemokines that are released by β-cells and 
immune cells, and by putative, immunogenic signals that are delivered by dying 
β-cells24. 
In the 1986 Eisenbarth proposed the current model for the development of 
the immune form of T1D25 and although our understanding has progressed 
significantly since then, the basic aspects of this model remain pertinent9,26,27 
(Figure 1). 
 
Figure 1 - The natural history of type 1 diabetes according to Eisenbarth’s model (originally 
proposed in 1986, then updated in 2001 and 2014)9. Latest additions and conjectures based 
on recent knowledge gains are shown in yellow boxes. 
This model postulates that everyone is born with a degree of susceptibility to 
develop T1D: for some this susceptibility is high, for others very low. 
Susceptibility is largely inherited, residing predominantly in the HLA genotypes 
DR and DQ, and to a lesser extent in a host of other genetic loci termed IDDM 
(insulin-dependent diabetes mellitus) susceptibility genes. The HLA locus is 
thought to confer about 50% of the genetic susceptibility, roughly 15% from two 
other genes – insulin-VNTR (IDDM2) and CTLA-4 (IDDM12) – with minor 
contributions from the other IDDM genes28–31. Both high risk (i.e., DR3/4, 
DQA1*0301-DQB1*0302, and DQA1*0501-DQB1*0201) and protective HLA 
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haplotypes (i.e., DQA1*0102-DQB1*0602, associated with diabetes resistance, 
and DR molecules such as DRB1*1401, associated with protection from 
diabetes) have been identified28. These susceptibility genes are thought to be 
important regulators of the immune response. Other genes associated with 
either rare syndromes including diabetes (i.e., AIRE and Foxp3) or other 
autoimmune conditions (i.e., PTPN22) might also provide important insights 
into the immune pathogenesis of T1D.  
In the beginning the autoimmune destruction of the insulin-producing β-cells 
in the pancreas is asymptomatic. This insidious process may evolve over a 
period of years (2-8 years)26.  
Continuing destruction of cells leads to progressive loss of insulin-secretory 
reserve with, in order, loss of first phase insulin secretion in response to an 
intravenous glucose tolerance test (Figure 2), then to clinical diabetes when 
insulin secretion falls below a critical amount, and finally, in most but not all 
those with T1D, to a state of absolute insulin deficiency25,30.  
 
Figure 2 - Schematic representation of insulin release in response to an intravenous injection 
of glucose. The green line is the normal response, the red line is the response in a patient with 
T1D32 
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Prediction of diabetes in relatives of a person with T1D and in the general 
population can be determined by risk assessment that includes HLA genotyping 
and measurement of autoantibodies combined with test of β-cell function33,34. 
Autoantibodies restricted to a single antigen have little prognostic value but an 
immune response that has spread to multiple antigens and is stable over time 
is highly predictive35,36. Individuals who have multiple islet autoantibodies are 
destined to develop T1D. 
The latency period offers an opportunity to intervene but oral insulin34, 
intranasal insulin37, parenteral insulin38 and nicotinamide39 have failed to arrest 
or retard the diabetes disease process. We can predict the development of T1D 
but do not yet have an effective preventive therapy40; whether screening 
should be performed outside the context of clinical studies is controversial41. 
Although it is often stated that symptoms occur when 90-95% of β-cells are lost, 
diagnosis of T1D can occur when roughly two-thirds of the islets are 
devoid of insulin-producing cells13,42. 
The early development of T1D involves progressive insulin deficiency, leading 
to weeks of symptomatic hyperglycaemia with polyuria, polydipsia and 
weight loss. If left untreated, the combination of insulin deficiency and stress 
(mediated through increased circulating levels of counter-regulatory hormones, 
including cortisol, catecholamines, growth hormone and glucagon) leads to 
lipolysis. Hepatic metabolism of free fatty acids as an alternative energy source 
(i.e., ketogenesis) results in accumulation of acidic intermediate and end 
metabolites (i.e., ketones and ketoacids). Diabetic ketoacidosis (DKA) then 
occurs in the presence of severe insulinopenia and is characterized by 
hyperglycaemia, acidosis and ketosis. Diagnosis of DKA has been traditionally 
made with a combination of hyperglycaemia (blood glucose >200 mg/dL), 
venous pH less than 7.3 and bicarbonate levels less than 15 mmol/L43. DKA at 
initial presentation is common, but rates vary strikingly between countries, 
ranging from approximately 15% to 70% in Europe and North America44 (32.9% 
in Italy, 6.6% of the severe form45). An inverse correlation between DKA 
frequency at diagnosis and the regional background incidence of T1D has been 
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described43. The key individual factors associated with greater risk of DKA are 
being less than 2 years old at presentation, being incorrectly diagnosed or 
having treatment delayed, belonging to an ethnic minority, lower socio-
economic status, lack of health insurance in the United States, lower parental 
education, lower body mass index (BMI) and preceding infection46–48.  
DKA remains the most common cause of mortality in T1D. The most 
devastating consequence of DKA is cerebral oedema with an incidence of 0.5% 
to 0.9%49,50. The mortality rate from cerebral oedema is 21% to 24%, and 
morbidity from serious neurologic sequelae occurs in 15% to 35% of cases48,51. 
Furthermore, DKA has a long-term impact on cognitive function, including a fall 
in intelligence quotient and persistent loss of short-term memory49.  
The “honeymoon” or remission period – characterized by an improvement 
in residual β-cell function with increasing concentrations of circulating C-
peptide and a lower requirement for exogenous insulin52–56 – takes place soon 
after clinical diagnosis and initiation of insulin therapy when some endogenous 
insulin secretion is restored to exhausted but not yet destroyed cells, and when 
insulin resistance associated with initial hyperglycaemia is lessened57,58. The 
phenomenon is thought to be due to an increase in insulin sensitivity58,59 and 
an alleviation of the destructive process in the islets of Langerhans. The 
insulin treatment reduces hyperglycaemia and the demand on the β-cells to 
secrete insulin, β-cell rest60, which, as exemplified by in vitro experiments, 
lowers their autoantigen expression61,62 and improves the resistance against 
destruction with β-cell toxins63,64. In general, β-cells are destroyed more 
rapidly when onset of clinical diabetes takes place at a young age, when 
there is also less likelihood of a long remission period (Figure 3). Thus, older 
individuals are more likely to respond soon after diagnosis to immune 
interventions aimed at preserving residual insulin secretion27.  
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Figure 3 - Younger children more rapidly lose endogenous insulin production, as evidenced by 
plasma C-peptide concentrations from the time of diagnosis of T1D. Data are stratified by age 
of onset: 5–14.9 years old (blue), 2–4.9 years old (orange) and <2 years old (purple). Toddlers 
have the lowest plasma C-peptide concentrations at diagnosis. The temporary partial remission 
experienced by older children is readily apparent and is notably absent in toddlers.65 
Among individuals who have had T1D for more than 5 years, most of the 
remaining islets are insulin deficient, containing a normal complement of other 
hormone-secreting cells (i.e., α-cells that secrete glucagon, δ-cells that secrete 
somatostatin, and PP-cells that secrete pancreatic polypeptide)13, thus T1D 
involves a selective loss of β-cells. Recent data suggest that although most 
patients with long-standing T1D have few β-cells, if any, there is evidence for 
β-cell regeneration in infants and very young children (but not in 
adolescents or adults)66,67. 
Highly sensitive and specific radioimmunoassay for the proinsulin C-peptide 
permit studies of residual β-cell function despite a patient being treated with 
insulin68. The use of the C-peptide is based on the observation that insulin and 
C-peptide are released in equimolar amounts from the cells. Fasting C-peptide 
is reduced, often to a level below the normal range (Figure 4). 
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Figure 4 - Schematic representation of fasting plasma C-peptide range in healthy individuals. 
The solid line is the average fasting C-peptide level for insulin-dependent diabetic patients in 
relation to duration of the disease in years32. 
The initial insulin treatment appears to increase the level of fasting C-peptide 
during the first 3-6 months after diagnosis. After that, C-peptide levels 
continuously decrease, reaching values below the detection limit of the assay 
(about 0.05 pmol/ml) after 3 to 4 years of T1D69–71. The extent to which fasting 
or stimulated levels of C-peptide reflect the residual mass of pancreatic β cells 
remains to be clarified. It is clear that, within hours, removal of exogenous 
insulin hampers the ability of a T1D patient to control blood sugar. However, it 
is not clear whether the residual amount of C-peptide and its fluctuation 
following dietary control or intensified insulin therapy reflect changes in the 
number or residual β-cells or in the function of those remaining β-cells. 
There is good evidence that the residual 10% of β-cell function has clinical 
benefit at the onset of symptoms. The Diabetes Control and Complications 
Trial (DCCT) identified a “virtuous circle” whereby residual insulin secretion 
resulted in better glucose control with less hypoglycaemia and slower 
progression to vascular complications72. Much investigation has been directed 
at arresting the disease process during the evolution of the disease and at 
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presentation40. The goal is to halt β-cell destruction, thereby lessening the 
severity of clinical manifestations and disease progression41. 
In the last years, interest in reversal of T1D diabetes has grown73. Currently, 
there are no approved agents to stop the autoimmune destruction of β-
cells after diagnosis of T1D9. In addition to preserving production of C-
peptide, a key goal is to induce immune tolerance against β-cells and 
thereby halt autoimmune destruction. Most approaches involve provision of 
self-antigen (i.e., vaccination with specific islet-cell proteins, such as insulin or 
GAD) or immune suppression. Disappointingly, after promising phase 1–2 
trials, phase 3 trials did not meet primary endpoints. Other phase 2 studies of 
immune modulators showed evidence of therapeutic efficacy in settings of 
recent-onset T1D; however, even with continued use, most did not show 
durable effects (Table 1)9. 
 
Table 1 - Agents assessed as immunomodulatory therapy to reverse T1D9 
Agent Study phase; year Main findings 
Insulin APL 
NBI-6042 
Phase 2; 2009 No change in metabolic response (i.e., C-
peptide preservation)74 
Anti-CD20 
Rituximab 
 
Phase 2; 2011  
 
Preservation of C-peptide concentrations at 1 
year, but no diff erence from placebo at 
2 years75 
Anti-CD3 
Teplizumab 
 
Phase 3; 2011  
 
Although phase 2 studies showed preservation 
of C-peptide concentrations, phase 3 trials 
(Protégé study)76 showed no change in 
metabolic respons and the study stopped early 
CTLA4 - 
immunoglobulin  
fusion protein  
Abatacept 
Phase 2; 2011 T-cell co-stimulatory modulation slowed 
reduction in β-cell function over 2 years, 
although preservation of C-peptide was seen for 
9.6 months77 
Anti-CD3 
Otelixizumab 
 
Phase 3; 2011 Although phase 2 studies showed preservation 
of C-peptide concentrations, a phase 3 trial 
showed no change in metabolic response78 
GAD65 protein 
Diamyd 
Phase 3; 2012 Phase 2 studies reported preserved C-peptide 
concentration, with no improvements in insulin 
needs. Two phase 3 trials did not meet 
endpoints79,80 
HSP60 
DiaPep277 
 
Phase 3; 2012 Phase 2 trials suggested increased C-peptide 
concentrations; a phase 3 trial noted C-peptide 
preservation at 1 year, but only in adults (age 
16-45 years) with T1D81 
	
26 
These results imply that single-agent immunosuppression alone might be 
insufficient to completely control the autoimmune destruction of β cells, or that 
more specific and targeted therapies are needed. 
Combination therapies that target several pathogenic pathways and improve 
β-cell viability might be needed to preserve endogenous insulin production in 
patients with T1D. Additionally, testing agents that target inflammation (i.e., 
anakinra [interleukin-1 receptor antagonist] and canakinumab [anti-interleukin-
1b compound]), alone or in combination could prove beneficial82.
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 3.	TRAIL	
 
Tumor necrosis factor [TNF]-Related Apoptosis-Inducing Ligand (TRAIL) 
(also known as Apo2 ligand or Apo2L) is a member of the TNF superfamily of 
proteins, whose best characterized function is the induction of apoptosis in 
tumour, infected, or transformed cells through activation of specific 
receptors83.  
Apoptosis is a process leading to cell death, whereby unrequired cells can be 
eliminated in order to safeguard multicellular organism health. There are two 
ways of signalling leading to apoptosis. One is called “intrinsic pathway”, 
because it is triggered by an intracellular signal, such as DNA damage, while 
the other is called “extrinsic pathway”, because it is triggered by an extracellular 
signal, which usually derives from cytotoxic cells of the immune system (Figure 
5)84.  
 
Figure 5 - TRAIL-receptor mediated signalling pathways. By binding its receptor TRAIL initiates 
cell death (apoptosis) via either intrinsic (mitochondria) or extrinsic pathway and/or induces the 
activation of survival genes resulting in cell proliferation/migration and inhibition of apoptosis.83 
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In particular, the extrinsic pathway is activated upon the binding of specific 
proapoptotic ligands, namely, FasL/CD95L and TNF-α, to their 
transmembrane receptors. This stimulates the trimerization of the 
transmembrane receptors and the formation of the death-inducing signalling 
complex (DISC), based on the recruitment of Fas associated death domain 
(FADD). Subsequently, FADD recruits both caspase-8 and caspase-10, which 
undergo autoactivation by proteolytic cleavage and which in turn activate 
caspase-3, caspase-6, and caspase-7, eventually executing the apoptotic 
program (Figure 5). 
TRAIL was independently identified by two different groups as the third pro-
apoptotic ligand that triggers the extrinsic pathway85,86. The name was 
chosen for the high homology of this protein to other TNF family members (the 
percentage of identity with FasL/CD95L and TNF-α is in fact 28% and 23%, 
respectively). The gene encoding for TRAIL is located on chromosome 3 at 
position 3q26. TRAIL gene locus spans approximately 20 kb and it has five 
exonic segments and four introns.  
In humans, TRAIL is expressed as a type II transmembrane protein of 281 
amino acids and it is composed of four parts: (1) an extracellular TNF-like 
domain; (2) an extracellular stalk; (3) a transmembrane helix; (4) a small 
cytoplasmatic domain.  
There is potential cleavage site in the extracellular domain at aminoacid 
position 114. TRAIL can be proteolytically cleaved by cysteine proteases and 
matrix-metalloproteinase(MMP)-2 to produce a soluble form of 24 kDa with 
biological activity. It is at this stage that the cysteine residue at position 230 
(Cys230) allows TRAIL to interact and assemble with other two molecules of 
TRAIL forming a trimeric ligand. These homotrimers are proapoptotic agonists 
that bind to their specific receptors (Figure 6).  
Unlike the other members of the TNF superfamily, TRAIL binds to a complex 
system of receptors with distinct affinities and different signaling outcomes.  
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Figure 6 - Schematic representation of TRAIL receptors. The binding of trimeric soluble TRAIL 
with death receptors TRAIL-R1 and TRAIL-R2 can induce either the activation of the caspase 
cascade, promoting cellular apoptosis, or the NF-κΒ signaling pathways. TRAIL also binds 
other 2 transmembrane receptors (TRAIL-R3 and TRAIL-R4) and one soluble receptor (OPG). 
TRAIL-R4, which has a truncated death domain, is not able to trigger the apoptotic signal, but 
may activate NF-κΒ pathway.87 
Four membrane receptors (not only death receptors but also decoy receptors) 
and a soluble receptor are known in humans, while mice express a unique 
apoptosis-inducing receptor for TRAIL. 
The human receptors for TRAIL are: 
- 2 death receptors (DR) which are both type I transmembrane proteins 
containing an intracellular death domain (DD) that classically stimulates 
apoptosis upon TRAIL binding by activating both caspases and nuclear 
factor (NF)-κΒ pathways: 
o TRAIL receptor 1 (TRAIL-R1) or death receptor 4 (DR4) or 
TNFRSF10A 88 
o TRAIL receptor 2 (TRAIL-R2) or death receptor 5 (DR5) or 
TNFRSF10B or TRICK2 or KILLER89,90 
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- 2 decoy receptors (DcR) which are transmembrane receptors that differ 
from DR in that their cytoplasmatic domain lacks an intact DD and 
apoptosis-inducing capability; they are not capable of activating caspase 
cascade, but may activate NF-κΒ and block apoptosis; they have been 
proposed to protect normal cells from apoptosis: 
o TRAIL receptor 3 (TRAIL-R3) or decoy receptor 1 (DcR1) or 
TRID or TNFRSF10C 91 
o TRAIL receptor 4 (TRAIL-R4) or decoy receptor 2 (DcR2) or 
TNFRSF10D 92 
- 1 soluble receptor that lacks both transmembrane and cytoplasmatic 
residues; it seems to inhibit TRAIL-induced apoptosis by competitive 
inhibition of TRAIL-binding to the death receptors TRAIL-R1 and TRAIL-
R2: 
o osteoprotegerin (OPG)93 
Depending on time, dose and location of TRAIL expression and engagement 
of special receptors, it may exert a beneficial as well as a destructive potential94.  
The first and best characterized function of TRAIL was its ability to induce 
apoptosis in transformed cells, such as malignant cells. Studies on TRAIL 
knockout mice have in fact demonstrated that mice without TRAIL are viable 
and fertile but more susceptible to tumour metastases, indicating that TRAIL 
regulates immune surveillance and host defence against tumour initiation 
and progression95,96. In particular, TRAIL seems to mediate the ability of NK 
cells and cytotoxic T lymphocytes to block tumour growth and metastasis 
development97,98. It should be noted that TRAIL-dependent killing by NK cells 
is believed to protect the organism also from infection99. Interestingly, one 
of the unique aspects of TRAIL, as compared to the other pro-apoptotic 
receptor agonists (PARAs)100,101, is that TRAIL has the ability to induce 
apoptosis preferentially in transformed cells, such as tumour or infected 
cells, while it would spare most normal cells, except thymocytes, neural cells 
and human hepatocytes102. 
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Another intriguing aspect of TRAIL is that it can apparently mediate also non 
apoptotic signalling. When TRAIL-R1 and TRAIL-R2 bind to TRAIL 
homotrimers they can stimulate not only pro-apoptotic pathways, but also pro-
survival pathways, such as NF-κΒ, ERK1/ERK2, and Akt103,104 (Figure 5). In 
particular the pro-survival signalling complex would still rely on DISC assembly, 
but instead of caspase activation, it would depend on the recruitment of TNF-
receptor-associated death domain (TRADD), TNF receptor-associated factor-2 
(TRAF2), receptor interacting protein (RIP), and the inhibitor of κΒ kinase (IκK). 
Once this complex has been assembled, it would then activate NFκΒ, PI3K/Akt 
(phosphatidyl inositol 3-kinase/protein kinase B), and MAPKs (mitogen-
activated protein kinases), including ERK (extracellular-signal-regulated 
kinases), as well as JNK (c-Jun N-terminal protein kinase) and p38, leading to 
survival signals (Figure 5). 
In regards to the ability of TRAIL to activate diametrically opposed 
pathways, it has been suggested that this may derive from differential cell 
responsiveness, rather than to the ligand properties. In this respect, it has 
been proposed that cell responsiveness to TRAIL could result from the balance 
between death and decoy receptors expressed on the cell surface. It is current 
view that this balance can be influenced by the cellular incorporation of specific 
intracellular proteins into “lipid rafts”. Lipid rafts are platforms consisting of a 
dynamic pool of cholesterol and sphingolipids, which recruit signalling 
molecules including cell surface receptors. Several studies have reported that 
there is a redistribution of TRAIL receptors and DISC components from “non-
rafts” into “lipid rafts” and it is current opinion that this is what could switch either 
cell apoptosis or survival upon TRAIL stimulation105,106.  
However, a correlation between TRAIL receptors balance (i.e., death/decoy 
receptor ratio) and protection versus susceptibility to apoptosis has never been 
clearly demonstrated and it is still under debate. 
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4.	TRAIL	AND	AUTOIMMUNITY	
 
During the last decade it has been revealed that TRAIL is clearly implicated 
not only in cancer but also in immunity. It has been shown to exert 
immunosuppressive and immunoregulatory functions important for immune 
homeostasis, immunosurveillance and autoimmunity. 
Although neither TRAIL nor TRAIL-R knockout mice develop spontaneous 
autoimmune diseases, TRAIL has consistently been shown to inhibit 
autoimmune diseases in a variety of animal models. 
Animal studies have shown that genetic loss of both FasL and TRAIL resulted 
in a condition that resembles to human autoimmune lymphoproliferative 
syndrome (ALPS), which is characterized by splenomegaly and 
lymphadenopathy, due to an accumulation of CD4–CD8– “double negative” T 
cells107. The fact that in this model TRAIL deficiency affected the severity of 
lymphocyte accumulation indicates that TRAIL contributes to the control of 
peripheral lymphocyte apoptosis, perhaps in a secondary or cooperative 
manner with respect to FasL. In addition, the finding that TRAIL deficiency led 
to ALPS2 development, which is characterized by abnormal dendritic cells 
accumulation108, suggests that TRAIL helps in getting rid of immature dendritic 
cells, by killing them before lymph node entry.  
Moreover, the observation that TRAIL-knockout mice had a severe defect in 
thymocyte apoptosis and were hypersensitive to both collagen-induced arthritis 
and streptozotocin(STZ)-induced diabetes initially suggested that TRAIL could 
be critically involved in the maintenance of central tolerance by the 
negative selection of autoreactive thymocytes109. Nevertheless, further 
studies have challenged this hypothesis. Cretney and colleagues could in fact 
not reproduce the finding that negative selection was impaired in TRAIL-
knockout mice110, nor that the adaptor protein FADD was essential for thymic 
negative selection111. Eventually, though, Corazza and colleagues reconciled 
these conflicting results by suggesting that in the thymus TRAIL is a response 
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modifier for mitochondrial apoptosis rather than a direct mechanism of thymic 
negative selection112, therefore implying that TRAIL is involved, although 
only indirectly, in thymic apoptosis and thymic negative selection. 
If central tolerance relies on thymic negative selection, peripheral tolerance is 
based on: (1) anergy induction; (2) presence of CD4+CD25+ regulatory T (Treg) 
cells; (3) termination of T cell immune responses, which depends on the 
activation-induced cell death (AICD). It is in fact through AICD or by eliminating 
activated immune cells that the organism prevents any potential autoimmune 
damage.  
One of the first observations suggesting TRAIL involvement in mature 
lymphocyte post stimulation apoptosis was that TRAIL induced apoptosis in 
T cells after sensitization with interleukin(IL)-2113. Subsequently, TRAIL was 
also found to play a role in AICD of human peripheral blood mononuclear 
cells113, which is consistent with the concept that this molecule helps in getting 
rid of potentially dangerous immune cells. Apart from AICD, TRAIL seems 
to regulate peripheral tolerance also by promoting the proliferation of Treg 
cells114,115. These are cells that play an essential role in maintaining immune 
tolerance, and when they are absent, such as in individuals with IPEX (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), there is 
an enhanced susceptibility to autoimmune diseases and diabetes. In addition 
to that, the third way whereby TRAIL could regulate peripheral tolerance is its 
ability to prevent primary T cell proliferation during the antigen-
independent T cell activation116.  
Interestingly, it seems that TRAIL affects adaptive immune cells not only by 
inducing cell death, but also by inhibiting their activation and expansion117. On 
one hand, it has been shown that differentiating CD4+ Th1 cells118 are 
selectively removed by TRAIL-mediated apoptosis119, which explains why 
the frequency of CD4+ Th1 cells is greater in TRAIL-knockout mice with respect 
to their controls114. Likewise, also CD8+ antigen-activated T cells, generated 
in the absence of CD4+ T cells (“helpless” CD8+ T cells), are removed by 
TRAIL-mediated apoptosis97. On the other hand, in CD8+ T cells TRAIL can 
	
34 
induce cell cycle arrest in G2/M phase (rather than apoptosis)120. 
Nevertheless, TRAIL can reduce T cell proliferation also by inhibiting calcium 
influx121. Not surprisingly, TRAIL is also involved in the regulation of plasma 
cell homeostasis, where it promotes apoptosis under specific conditions, 
which include the loss of both CD40 expression and NFκΒ activation122. 
Consistent with this, administration of neutralizing anti-TRAIL antibodies 
markedly increases serum autoantibody levels in autoimmune prone 
mice123.  
To complete the picture, TRAIL seems to have also anti-inflammatory 
actions. For example, Renshaw and colleagues demonstrated that neutrophil 
apoptosis is accelerated by leucine zipper-tagged TRAIL, which may represent 
a potential mechanism of neutrophil clearance at sites of inflammation124. 
Another argument in favour of TRAIL anti-inflammatory actions is what it does 
on atherosclerosis125, which should in fact be considered as an inflammatory 
disease126. In in vitro studies, TRAIL significantly reduced leukocyte/endothelial 
cell adhesion by down-regulating chemokine expression127. In in vivo studies, 
TRAIL delivery reduced the extent of aortic atherosclerosis, possibly by 
inducing macrophage apoptosis128, and consistent with this finding, DiBartolo 
and colleagues reported a reduction in macrophage accumulation in the 
atherosclerotic plaques of TRAIL-knockout mice129. 
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5. TRAIL AND DIABETES  
 
The function of TRAIL in the pathogenesis of diabetes was initially recognized 
in rodent models, suggesting that TRAIL might protect against T1D83,87. 
The potential role of TRAIL in T1D was first explored in 2003 by Lamhamedi-
Cherradi and colleagues109: TRAIL-deficient mice were hypersensitive to 
STZ-induced diabetes and collagen-induced arthritis, and developed 
heightened autoimmune responses109.  
The same group examined the consequences of TRAIL blockade or TRAIL 
deficiency in two animal models of T1D130. The first animal model consisted of 
NOD (non obese diabetic) mice injected with a soluble TRAIL receptor 
(sDR5/TRAIL-R2) in order to block TRAIL functions. TRAIL blockade by sDR5 
injection significantly increased T1D incidence and accelerated T1D onset 
in NOD mice. Moreover, in this study sDR5 injection led to a greater islet 
inflammation as well as to enhanced cellular and humoral immune 
responses, with an increase in T cells proliferation and pro-inflammatory 
response as well as higher levels of anti-GAD-65130. The second animal model 
consisted of normal and TRAIL-knockout mice injected with multiple low-dose 
STZ in order to destroy β-cells and therefore to cause diabetes. The findings in 
the diabetic TRAIL-knockout mice recapitulated those observed in the sDR5 
treated NOD mice: both the incidence and the degree of islet inflammation 
were significantly enhanced in TRAIL-deficient animals130. 
Consistently with these observations, adenoviral delivery of TRAIL 
significantly lowered diabetes incidence in NOD mice131. In STZ-induced 
diabetic rats undergoing pancreatic islet transplantation, viral TRAIL 
administration prolonged normal blood glucose levels up to 60 days, and 
displayed significantly reduced pancreatic insulitis compared to controls132. 
Furthermore, administration of recombinant TRAIL significantly reduced 
hyperglycemia in STZ-treated mice, associated with larger pancreatic 
islets133. 
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Anyhow, the molecular mechanisms whereby TRAIL blockade exacerbates 
T1D and, on the other side, its delivery ameliorates the natural history of the 
disease have only partly been clarified.  
The  potential mechanisms underlying TRAIL protective effects include 
interaction with the immune activation and innate immunity, such as pro-
apoptotic actions on autoreactive T cells134, stimulation  of Treg cells114, anti-
inflammatory effects135 and reduction of cytokine-mediated cytotoxicity in 
pancreatic islets136. 
One hypothesis is that TRAIL could induce T cell death or inhibit their 
activation. This has been partly confirmed by Mi and colleagues who showed 
that TRAIL suppressed in vitro the proliferation of autoreactive T cells 
isolated from diabetic NOD mice134. This effect was explained by the finding 
that TRAIL up-regulated p27 expression and simultaneously inhibited IL-2 
production by autoreactive T cells. In this respect, it has indeed been shown 
that the up-regulation of p27 stops the progression of the cell cycle, preventing 
the progression of T cells through the G1 restriction point of the cell cycle, and 
therefore anergizing autorective T cells137. On the other hand, cell exposure to 
IL-2 has been shown to promote the degradation of p27 and the entry into S 
phase137; therefore IL-2 inhibition by TRAIL could be an additional 
mechanism whereby it anergizes diabetogenic T cells.  
Another hypothesis is that TRAIL could promote β-cell survival87. In vitro 
experiments performed on rat insulinoma cells (INS-1), which are used as a 
model for the study of pancreatic β-cells, have shown that exposure to soluble 
TRAIL does not affect β-cell viability, and, by promoting the activation of NF-
κΒ, upregulates the expression of the decoy receptor TRAIL-R3, which in turns 
should prevent apoptosis138. In this context, it is noteworthy that specific 
increase of TRAIL and TRAIL-R3 expression in the pancreatic islets in NOD 
mice, upon acceleration of T1D disease by STZ injection, has been proposed 
as part of a defensive strategy of the islets against the infiltrating leukocytes132. 
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Kang and colleagues have further investigated TRAIL protective effects in T1D 
animal model, demonstrating that they could be partly attributed to the 
elevation of tissue inhibitor of metalloproteinase-1 (TIMP-1) levels that 
follows TRAIL delivery131. In vivo, TIMP-1 elevation induced by TRAIL delivery 
markedly reduced the pancreatic activity of MMP-9, thus contributing to the 
preventive effect of TRAIL on T1D in NOD mice131. Of interest, it has been 
previously reported that plasma concentrations of MMP-9 are elevated in 
diabetic patients and that increased MMP-9 is diabetogenic as it cleaves 
insulin139–141. The in vivo data are further supported by in vitro data showing 
that the addition of TIMP-1 significantly reduces INS-1 cells death131, 
consistently with a previous report showing that TIMP-1 prevents cytokine- 
mediated dysfunction and cytotoxicity in pancreatic islets and β-cell136 
(Figure 7). 
 
 
Figure 7 – Effects of TRAIL in pancreatic β-cells. TRAIL can stimulate caspase- or NF-κΒ-
mediated apoptosis, or survival via NF-κΒ, tissue inhibitor of metalloproteinase-1 (TIMP-1), and 
possibly suppressor of cytokine signaling-1 (SOCS-1). TRAIL not only promotes insulin 
production/secretion from β-cells but also prevents insulitis, in part via TIMP-1 inhibitory effects 
on leukocyte infiltration in the pancreas142. 
	
38 
In humans, TRAIL expression is detected in the islets of acute-onset T1D 
patients but is absent in healthy individuals143 and this corresponded with 
increased TRAIL expression in T cell lines derived from new-onset T1D 
patients, upon stimulation with β-cell antigens143, and in peripheral T cells from 
T1D patients144.  
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6. DULANERMIN: A POTENTIAL THERAPEUTIC 
CHANCE 
 
Dulanermin (AMG 951) is the recombinant human soluble protein 
corresponding to amino acids 114-281 of TRAIL145. Because of its potential 
antineoplastic activity, it has been studied as a PARAs in cancer therapy. 
Dulanermin binds to and activates death receptors (TRAIL-R1/R2), which may 
activate caspases and induce p53-independent apoptosis in TRAIL-R1/R2-
expressing tumour cells.  The pro-apoptotic cell surface receptors TRAIL-R1 
and -R2 are overexpressed by a variety of cancer cell types.  
Although TRAIL-based therapies have been currently used mainly in cancer, 
the therapeutic value of TRAIL-based treatments in autoimmune diseases has 
been proposed146. A number of therapeutic strategies involving TRAIL have 
been used to treat various experimental autoimmune diseases in animal 
models (Figure 8)147. 
 
 
Figure 8 - Summary of the main effects of TRAIL-based therapy in different experimental 
models of autoimmune diseases (EAT: experimental autoimmune thyroiditis; EAE: 
experimental autoimmune encephalomyelitis; CIA: collagen induced arthritis; AIA: antigen 
induced arthritis; AA: adjuvant arthritis, RA: rheumatoid arthritis)147  
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In phase 1b and 2 study148–150, although the combination of Dulanermin with 
standard chemotherapy did not seem to significantly increase antitumoral 
activity, it was well tolerated with no toxicity or adverse effects on 
patients151. 
The existence of Dulanermin as a potential therapeutic perspective with a safe 
profile in diabetes makes more considerable the understanding of TRAIL in the 
natural history and progression of T1D and its complications.  
Dulanermin might be considered as a therapeutic option for the treatment of 
T1D, either administered alone or in combination with other therapeutic 
strategies (i.e., immunosuppressant or islet transplantation), in the early onset 
or in the late phase of T1D, in order to attenuate the autoimmune and the 
inflammatory response133. 
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CHAPTER 2  
STUDY I 
WHAT HAPPENS TO TRAIL LEVELS  
IN CHILDREN WITH TYPE 1 DIABETES? 
 
Published in Acta Diabetologica 
 
Tornese, G., Iafusco, D., Monasta, L., Agnoletto, C., Tisato, V., Ventura, A., 
Zauli, G., Secchiero, P. (2014). The levels of circulating TRAIL at the onset of 
type 1 diabetes are markedly decreased in patients with ketoacidosis and with 
the highest insulin requirement. Acta Diabetologica, 51(2):239–46. 
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AIM	
 
The aim of this study was to analyse the serum levels of TRAIL in a paediatric 
retrospective cohort, mainly including T1D patients and age-matched healthy 
control subjects. 
MATERIALS	AND	METHODS	
 
Patients and sample collection  
Sera of paediatric individuals followed at the Second University of Naples were 
obtained from patients with T1D (n=387), healthy subjects without islet-specific 
autoantibodies (n=98, indicated as controls), and healthy subjects with the 
presence of at least one islet-specific autoantibody (n=22, “AutoAb POS/T1D 
NEG”). 
Among T1D patients, blood was taken at onset (within the first 48 h after 
diagnosis, n=167) or at later times after onset (n=220). Parents provided 
informed consent to blood sample drawing and storage for research purposes, 
in accordance with the Declaration of Helsinki of 1975. Data included age, sex, 
diagnosis, age at onset (if T1D) or at first visit (if not-T1D), age at blood sample 
drawing, HbA1c, onset with diabetic ketoacidosis (DKA), islet-specific 
autoantibodies detected (ICA, GADA, IA2A, IAA, ZnT8A), and the presence of 
other autoimmune diseases. 
After onset, all T1D patients were placed on intensive insulin therapy consisting 
of three daily regular insulin injections at meals and NPH insulin at lunch and 
bed time. The regimen was then individually tailored during the follow-up, with 
the introduction of rapid- and/or long-acting analogues. Insulin daily 
requirements (in U/Kg/d) were calculated dividing the total daily insulin dose (in 
units) by patient weight (in kilograms). 
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Laboratory analyses  
A1c values were measured by using a point-of-care platform (DCA-2000 
Analyzer, Siemens/Bayer, Munich, Germany). ICA antibodies were measured 
with an indirect immunofluorescence assay using cryosections of fresh frozen 
human blood group O pancreas as substrate; GADA, IA2A, and IAA antibodies 
were detected by radioimmunoassay (RIA) commercial kits (Biochem Immuno-
Systems, Italy for GADA and IA-2A; CIS Italy for IAA); ZnT8A antibodies were 
assessed by ELISA commercial kits (RSR limited, United Kingdom). 
Serum TRAIL was measured in duplicate by using a commercially available 
ELISA kit (R&D Systems, Minneapolis, MN, USA) following the manufacturer’s 
instructions. Selected samples were run in each ELISA plate as internal 
controls, confirming the reproducibility of determinations over time. 
 
Statistical analysis 
Box plots were used to show the median, interquartiles, and minimum and 
maximum values for each group of data. After verifying that the TRAIL serum 
values of this study did not distribute normally (skewness and kurtosis joint 
normality test), we applied the nonparametric Mann–Whitney test or the 
Kruskal–Wallis test for the equality of populations to compare the TRAIL values 
among different populations. The Bonferroni correction was applied if multiple 
two-by-two comparisons were necessary after conducting a Kruskal–Wallis 
test. Correlation coefficients were calculated with the Spearman’s rank 
coefficient ρ. A p value <0.05 was considered statistically significant.  
In the graphs, horizontal bars are median; upper and lower edges of box are 
75th and 25th percentiles; lines extending from box are 10th and 90th  percentiles. 
Asterisk (*) means a p value <0.05. 
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RESULTS	
	
The cohort of individuals analysed in the present study included 387 patients 
with T1D and 98 age-matched healthy control subjects. Twenty-two subjects 
with positivity for autoantibodies, but without overt T1D (AutoAb POS/T1D 
NEG), were also included (Table 2).  
 
Table 2 - Characteristics of the subjects included in the study. Continuous variables are 
presented as median with interquartile range (IQR) in parenthesis; categorical variables are 
presented either as number or percent unless otherwise indicated. * Subjects positive for 
autoantibodies (GADA, IA2A, ICA, IAA, or ZnT8A), ** Pathologies of autoimmune origin 
including Addison’s disease, vitiligo, juvenile idiopathic arthritis, multiple sclerosis, psoriasis 
 
 Controls AutoAb POS/ 
/T1D NEG 
T1D 
Subject number 98 22 387 
Sex, female/male (%) 35/65 23/77 44/56 
Age at blood drawing (years) 9.2 (5.8-12.0) 11.0 (7.5-13.5) 9.3 (5-4-12.7) 
Age at onset (years) N/A 10.2 (6.4-13.1) 8.6 (4.7-11.8) 
A1c (%) 5.0 (4.8-5.2) 5.6 (5.1-5.8) 10.9 (9.3-12.5) 
A1c (mmol/mol) 33.3 (31.1-35.5) 36.6 (32.2-39.9) 95.6 (78.1-113-1) 
DKA N/A N/A 250 
Autoantibodies positivity (%)* 0 100 87 
Hashimoto’s thyroiditis 0 0 70 
Coeliac disease 0 2 22 
Other pathologies  
of autoimmune origin** 
0 0 10 
  
The circulating levels of TRAIL assessed in patients with T1D (median 65.7 
pg/ml) were significantly lower (p<0.001) when compared with healthy control 
subjects (median 83.1 pg/ml) (Figure 9).  
Moreover, TRAIL levels in T1D patients were significantly lower also when 
compared to the AutoAbPOS/T1DNEG subjects (median 77 pg/ml; p=0.030) 
(Figure 9). On the other hand, preliminary data indicate that TRAIL levels in 
paediatric patients affected by maturity-onset diabetes of the young (MODY, 
n=10) were not significantly different from healthy controls (median 81 pg/ml; 
p=0.037). 
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Figure 9 - Levels of circulating TRAIL in healthy control subjects (controls, n=98), patients with 
T1D (n=387), subjects with positivity for islet-specific autoantibodies, but without overt T1D 
(AutoAbPOS/T1DNEG, n = 22).  
 
The serum levels of TRAIL in the T1D patient cohort were evaluated with 
respect to relevant demographic, biochemical, and clinical markers. No 
significant differences were observed in relation to the sex (p=0.409), and no 
significant correlations were observed between serum TRAIL and age of the 
patients (ρ=-0.022, p=0.655) as well as between serum TRAIL and HbA1c 
levels (ρ=-0.068, p=0.353).  
Moreover, we excluded the possibility that differences in TRAIL levels could 
depend from long sample storage, since no significant differences were 
observed in TRAIL value between samples analysed within 36 months after 
blood drawing and samples stored for more than 36 months and up to 200 
months (Figure 10). 
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Figure 10 -	Levels of circulating TRAIL according to the sample storage time: within 36 months 
after blood drawing and samples stored for more than 36 months and up to 200 months. 
 
Subsequently, in consideration of the role of TRAIL in controlling autoimmunity, 
we analysed whether TRAIL levels exhibited significant modulation in 
relationship to the presence of islet-specific autoantibodies (ICA, GADA, IA2A, 
IAA, ZnT8A). T1D patients with islet-specific autoantibody were 87% and did 
not differ in terms of circulating TRAIL levels from T1D autoantibody negative 
(Figure 11). When we analysed the circulating levels of TRAIL in relation to the 
positivity to each single autoantibody, we found differences close to be 
significant (p=0.058) only in association with the positivity/negativity for ICA 
autoantibody, with TRAIL levels lower in the ICA-positive patients (median 61.5 
pg/ml) with respect to the ICA-negative ones (median 74.6 pg/ml) (Figure 11).  
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Figure 11 - Levels of circulating TRAIL in patients with negative (n=41) or positive (n=281) islet-
specific autoantibodies (GADA, IA2A, ICA, IAA, or ZnT8A) and in relationship to the positivity 
or negativity for the ICA autoantibody (AutoAb).  
 
 
Moreover, the analysis of TRAIL levels in relation to the presence of other 
concomitant autoimmune disorders (celiac disease, Hashimoto’s thyroiditis, 
Addison’s disease, vitiligo, juvenile idiopathic arthritis, psoriasis, multiple 
sclerosis) in the T1D patients did not reveal any significant difference, both 
when considered together (Figure 12) or separately (for celiac disease and 
Hashimoto’s thyroiditis). 
	
49 
 
Figure 12 - Levels of circulating TRAIL in T1D patients with or without other concomitant 
autoimmune disease(s). The levels of TRAIL were analysed by comparing T1D patients with or 
without other concomitant autoimmune diseases.  
 
Since the T1D serum samples assessed derived from blood harvesting 
performed at different times from T1D onset, we evaluated the levels of 
circulating TRAIL in relation to the time from diagnosis, by dividing the samples 
in three main temporal intervals: ‘‘onset’’ (within 48 h from diagnosis; n=167), 
‘‘first year’’ (mean 95 days; n=108), and ‘‘> 1 year’’ after diagnosis (mean 483 
days; n=112). TRAIL values appear to significantly increase with time of blood 
drawing from the onset of T1D (Spearman’s rank correlation: ρ=0.183, p 
<0.001). Kruskal–Wallis equality-of-populations rank test showed a significant 
difference in TRAIL values among categories (p=0.001). We thus adopted a 
Mann–Whitney rank-sum test to verify which categories were different from 
each other, in terms of TRAIL values, applying a Bonferroni correction 
(p<0.016). TRAIL values at onset (median 61.2 pg/ml) were significantly lower 
than the levels measured at later time points after diagnosis, both with respect 
to the ‘‘first year’’ (median 71.3 pg/ ml; p=0.003) and to ‘‘>1 year’’ after diagnosis 
(median 70.0 pg/m; p=0.002) (Figure 13). 
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Figure 13 - The lowest levels of circulating TRAIL are at T1D onset. Serum levels of TRAIL 
were analysed in relation to the time from diagnosis by dividing the patient samples in three 
main temporal intervals: “onset” (n = 167), “≤1 year” (n = 108), and “>1 year” (n = 112) after 
diagnosis.  
 
Therefore, although reduction in TRAIL levels with respect to healthy controls 
was marked at onset, it persisted also in patients analysed >1 year from 
diagnosis. 
 
Subsequently, in order to investigate whether the levels of circulating TRAIL 
might be related with the severity of the disease, we have analysed the levels 
of circulating TRAIL at onset in relation to the presence or absence of DKA. In 
T1D patients with DKA at onset (n= 135), TRAIL levels (median 58.7 pg/ml) 
were significantly lower (p<0.0005) than in patients without DKA at diabetes 
onset (n=32; median 73.1 pg/ml) (Figure 14).  
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Figure 14 - The lowest levels of circulating TRAIL are at T1D onset in patients with 
ketoacidosis. The levels of TRAIL at T1D onset were analysed by comparing patients with 
(n=135) or without DKA (n=32).  
 
Moreover, for a subgroup of T1D patients (n=70), for which we had insulin 
requirements at 3-month intervals up to 21 months of follow-up, we analysed 
the rank correlation between TRAIL levels at onset and daily insulin 
requirements. With the exception of the ‘‘3 months’’ time point, the TRAIL levels 
at onset were significantly and negatively correlated at the insulin daily 
requirement (U/Kg/day) at all time analysed up to 21 months after discharge 
(Table 3). 
 
Table 3 - Insulin daily requirements by 3-month intervals (since onset of T1D and up to 21 
months) and correlation with TRAIL levels at onset. Correlation coefficients were determined 
by Spearman’s analysis. (IQR: interquartile range)  
 Insulin daily requirements (U/kg/d) Correlation with TRAIL at onset 
 Median (IQR) ρ (p value) 
Onset 0.71 (0.59-0.90) -0.36 (0.001) 
3 months 0.47 (0.39-0.67) -0.09 (0.451) 
6 months 0.46 (0.29-0.58) -0.29 (0.015) 
9 months 0.47 (0.29-0.61) -0.28 (0.025) 
12 months 0.49 (0.33-0.66) -0.29 (0.021) 
15 months 0.50 (0.34-0.72) -0.27 (0.025) 
18 months 0.61 (0.46-0.80) -0.27 (0.031) 
21 months 0.65 (0.48-0.77) -0.27 (0.027) 
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CHAPTER 3 
STUDY II	
WHAT HAPPENS TO TRAIL LEVELS 
AT TYPE 1 DIABETES ONSET 
AND/OR DURING KETOACIDOSIS? 
AND WHAT THEREAFTER?  
 
Published in Acta Diabetologica 
 
Tornese, G., Tisato, V., Monasta, L., Brumatti Vecchi, L., Zauli, G., Secchiero, 
P. (2015). Serum TRAIL levels increase shortly after insulin therapy and 
metabolic stabilization in children with type 1 diabetes mellitus. Acta 
Diabetologica, 52(5):1003-6.  
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AIM	
	
The aim of this study was to analyse the evolution of circulating TRAIL levels in 
a pilot group of paediatric patients admitted at Emergency Department for T1D, 
from the time of hospital admission throughout the re-establishment of a normal 
metabolic balance and up to 18 months of clinical follow-up.  
Moreover, the serum levels of TRAIL in T1D patients were analysed in relation 
to the metabolic status.	
MATERIALS	AND	METHODS	
 
Patients and sample collection 
A total of 80 blood samples were obtained from 11 paediatric patients  admitted 
for T1D onset or secondary diabetic ketoacidosis (DKA) at the Emergency 
Department of the Institute for Maternal and Child Health ‘‘Burlo Garofolo’’ of 
Trieste (Italy) (Table 4).		
Sample for blood gases was taken at admission to verify the presence of DKA 
in clinical suspicion of T1D or in patient with pre-existing uncontrolled T1D.  
DKA was defined as “mild” when pH was 7.2-7.3 and/or HCO3 10-15 mEq/l. 
“moderate” when pH was 7.1-7.2 and/or HCO3 5-10 mEq/l. and “severe” when 
pH was <7.1 and/or HCO3 <5 mEq/l. When DKA was excluded (pH >7.3 and 
HCO3 >15 mEq/l). no additional CBG were performed. In case of DKA. patients 
were treated according to ISPAD guidelines43; blood glucose and blood gases 
were repeated as per protocol until stabilization and serum TRAIL was 
evaluated in each blood sample.  
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Table 4 - Characteristics of the subjects included in the study 
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1 F 14.3 Post-pubertal 26.03 +1.42 Secondary DKA severe 753 6.91 6 8.0 - 64 N/A 0.65 
2 M 13.7 
In 
established 
puberty 
20.20 -0.17 
Secondary DKA mild 291 7.26 14 9.6 - 81 N/A 0.6 
3 M 8.6 Pre-puberatal 14.38 -0.62 New onset moderate 302 7.12 13 13.3 -122 0.26 0.7 
4 M 12.2 
In 
established 
puberty 
14.76 -2.06 
New onset moderate 567 7.2 10 11.8  105 0.25 0.85 
5 F 7.0 Pre-puberatal 18.94 +0.98 New onset moderate 343 7.18 11 12.2 - 110 0.35 0.94 
6 F 5.8 Pre-puberatal 13.91 -1.38 New onset mild 570 7.34 11.5 10.7 - 93 N/A 0.97 
7 M 12.6 
In 
established 
puberty 
26.05 +1.48 
New onset none 398 7.45 25 8.6 - 70 2.56 0.2 
8 F 11.6 
In 
established 
puberty 
16.22 -1.25 
New onset none 593 7.56 24 11.3 - 100 0.67 0.75 
9 F 16.8 Post-pubertal 16.10 -2.63 New onset none 394 7.44 25 8.3 - 67 0.59 0.52 
10 M 9.8 Pre-puberatal 14.85 -1.49 New onset none 270 7.32 17 12.0 - 108 0.21 0.75 
11 M 9.8 Pre-puberatal 16.74 -0.45 New onset none 367 7.41 24 9.7 - 83 0.37 0.31 
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Once metabolic stabilization has been obtained, all patients were placed or 
restarted on intensive subcutaneous insulin therapy consisting in “basal bolus” 
scheme (with 3 daily rapid-acting analogue insulin injections at meals and 1 
long-acting analogue insulin at bedtime) to reach optimal glycaemic levels 
Insulin daily requirement (in U/kg/day) was calculated dividing the total daily 
insulin dose (in Units) at discharge by patient weight (in kilograms).  
A blood sample was taken to determine TRAIL levels before hospital discharge 
and additional blood samples were taken from each patient before hospital 
discharge and every 6 months during the clinical follow-up.  
For all patients (including patient 7 which was overweight [>85th centile] and 
had high non-fasting C-peptide levels) the presence of diabetes-associated 
autoantibodies together with the lack of signs of insulin resistance (i.e. 
acanthosis nigricans), reasonably excluded T2DM. as well as monogenic 
diabetes 
Parents provided informed consent to blood sample drawing for research 
purposes. in accordance with the Declaration of Helsinki of 1975. The study 
was approved by the Bioethics Committee of the IRCCS ‘‘Burlo Garofolo’’ 
(Trieste, Italy; RC 18/13). 
 
Laboratory analyses  
Blood gases were measured by using ABL800 Flex (Radiometer, Brønshøj. 
Denmark).  
Blood glucose level was measured via a hexokinase enzymatic reaction by 
Cobas 6000 (Roche Diagnostics, Indianapolis, IN, USA).  
A1c was assessed using turbidimetric inhibition immunoassay by Cobas 
Integra 400 Tina-quant Hemoglobin A1c Gen.2 (Roche Diagnostics, 
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Indianapolis, IN, USA). 
C-peptide was estimated using a validated chemiluminescent assay on the 
Immulite 2000 (Siemens Healthcare Diagnostics, Deerfield, IL, USA).   
Serum TRAIL was measured in duplicate by using a commercially available 
ELISA kit (R&D Systems. Minneapolis, MN, USA) following the manufacturer's 
instructions.  
 
Statistical analysis 
Differences between values at two different time points were evaluated with a 
pairwise sign-rank Wilcoxon’s test. Correlation coefficients were calculated with 
the Spearman’s rank coefficient ρ. A p value <0.05 was considered statistically 
significant, after applying a Bonferroni correction if multiple rank-correlations 
were calculated simultaneously. 
In the graphs, horizontal bars are median; upper and lower edges of box are 
75th and 25th percentiles; lines extending from box are 10th and 90th  percentiles. 
Asterisk (*) a p value <0.05. 
	
RESULTS	
 
The main demographical and clinical characteristics of the paediatric patients 
enrolled in the present study are summarized in Table 4.  
Comparative analysis of the circulating TRAIL levels, showed median TRAIL 
level at admission of 52.8 pg/ml, with the lowest levels measured in the patients 
with DKA (median 47.9 pg/ml) with respect to patients without DKA (median 
76.14 pg/ml). 
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Of interest, in all patients included in the study, we documented a significant 
increase of TRAIL levels (p<0.01, using the sign-rank pairwise Wilcoxon test) 
at the time of discharge (median of time between the two measurement was 
2,5 days) with a median value of 100.3 pg/ml (Figure 15). A further significant 
(p<0.05) increase was documented after 6 months, reaching median values of 
TRAIL of 147.3 pg/ml that were maintained without significant modulations also 
in the subsequent time points/assessments up to 18 months (Figure 16). 
 
Figure 15 - Circulating TRAIL levels were monitored in serum samples collected at the 
admission and discharge in patients admitted to Emergency Department with T1D at onset 
and/or DKA.  
	
Figure 16 - Circulating TRAIL levels in serum samples collected at the indicated time points of 
the clinical history of the T1D paediatric patients enrolled in the study. 
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As for clinical protocol, in the patients with DKA (n=6) upon admission between 
5 and 10, blood samples were taken for each subject before reaching 
normalization of venous blood gas and/or blood glucose. This allowed us to 
monitor TRAIL levels also at the time points corresponding to metabolic 
stabilization (median time between admission and stabilization of 15.5 h; IQR 
10.1–20.9). Analysis of TRAIL levels in relationship with all the 
clinical/metabolic parameters revealed a significant (p<0.05) correlation only 
between TRAIL levels and HCO3  (Spearman’s rank correlation, ρ=0.4944, 
p=0.0014), BE (ρ=0.4405, p=0.0044), pH (ρ=0.368, p=0.0193), pCO2 
(ρ=0.3962, p= 0.0114) (Figure 17). 
 
 
Figure 17 - Correlation analyses between TRAIL circulating levels and clinical parameters 
related to the metabolic status of patients. Positive correlation between TRAIL and base excess 
(BE) as well as between TRAIL and bicarbonate (HCO3) are shown		
 
	
61 
	
CHAPTER 4 
STUDY III	
WHAT HAPPENS IN LONG-STANDING  
TYPE 1 DIABETES? 
ARE TRAIL LEVELS CORRELATED  
WITH MARKERS OF  
RESIDUAL Β-CELL MASS,  
INFLAMMATION OR AUTOIMMUNITY? 
 
Manuscript in preparation 
 
Tornese, G., Marcovecchio, M.L., Wicker, L.S., Secchiero, P., Todd, J.A., 
Dunger, D.B. Does TRAIL relate to measures of beta-cell function, general 
inflammation and immune activation in young people with T1D? 
This study was supported by the JDRF, the Wellcome Trust (061858, 076113 and 091157), the 
National Institute for Health Research Cambridge Biomedical Research Centre and the JDRF 
UK Centre for Diabetes – Genes, Autoimmunity and Prevention Grant (4-2007-1003). The 
research leading to these results has received funding from the European Union’s 7th 
Framework Programme (FP7/2007-2013) under grant agreement no. 241447 (NAIMIT). The 
Cambridge Institute for Medical Research (CIMR) is in receipt of a Wellcome Trust Strategic 
Award (100140). The NFS is funded by the JDRF, the Wellcome Trust and Diabetes UK.  
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AIM	
 
The aims of this study were: 
(1) to determine factors modulating levels of circulating TRAIL and over time 
changes in TRAIL;  
(2) to assess whether there was an association between TRAIL and residual 
beta-cell function, as assessed by C-peptide levels;  
(3) to assess whether TRAIL relate to other inflammatory/immune markers, in 
particular high-sensitivity CRP (hs-CRP) and soluble CD25 (sCD25).   
MATERIALS	AND	METHODS	
 
Patients and sample collection 
Four hundred fifty-one non-fasting serum samples for measuring TRAIL, 
sCD25, hsCRP and C-peptide levels were available from 232 young people 
followed in the Nephropathy Family Study (NFS). The NFS is a prospective 
study that has, since 2000, recruited more than 1,000 adolescents (10–
18 years) with T1D and has followed them longitudinally 152. For the present 
analysis, 219 patients had two available stored serum samples collected at a 
median time interval of 1.2 years [1.0-1.7]. No significant differences were found 
in age at diagnosis, sex distribution and glycemic control between selected 
subjects and the entire cohort.  
Ethics approval was obtained from the ethics committee, with written consent 
from participants or parents with assent from the children. All data and samples 
are treated as confidential. Samples and data are identifiable by a unique 
barcode only, and volunteers are free to withdraw from these projects at any 
time.  
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Laboratory analyses 
All plasma and serum samples were stored at −80°C until analyses were 
performed. sCD25 and C-peptide were already determined for a previous 
study153.  
Serum TRAIL was measured on frozen serum aliquots by using a commercially 
available ELISA kit (R&D Systems, Minneapolis, MN) following the 
manufacturer’s instructions, as previously described154. The lower limit of 
detection of this assay was 15.6 pg/ml.  
hs-CRP (Cardiac C-Reactive Protein) was run on the Siemens Dimension RXL 
auto analyser. The lower limit of detection of this assay was 0.1 mg/l and hs-
CRP levels >10 mg/l were excluded from the analysis, as they are likely related 
to infections or other acute inflammatory processes 155,156.  
Since circannual rhythms have been described to significantly increase CRP 
concentration157 and a seasonal variation of the incidence of T1D in children 
under 15 years of age is a known phenomenon 158 we also considered seasonal 
variation of variables (as a 4-level factor variable, using the 21st day of June, 
September, December and March as cut-off to define summer [1], autumn [2], 
winter [3] and spring [4]). 
 
Statistical analysis 
Data are mean ±SD or median [interquartile range].  
Differences between values at two different time points were evaluated with a 
pairwise sign-rank Wilcoxon’s test. 
Due to non-normal distribution, TRAIL, A1c, C-peptide, sCD25, and hs-CRP 
were Log (10) transformed for analyses requiring normal distribution. 
Association between variables was performed with repeated measures logistic 
regression using Generalized estimating equations (GEE) to account for the 
lack of independence when two samples were available for the same subject 
and results are expressed as β coefficients. 
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Changes over time (Δ) of variables were calculated as: (variable at time 2 – 
variable at time 1)/variable at time 1. Association between Δ of variables was 
performed with linear regression analysis and results are expressed as β 
coefficients. 
SPSS version 20 was used for the analyses. Statistical significance was defined 
by a p values <0.05. 
RESULTS	
	
Two hundred thirty-two subjects were enrolled in the present study (59% 
female), with a median age at diagnosis of 8.9 years [5.3-11.1]. Two hundred 
nineteen subjects had two available samples and the median time between the 
two visits was 1.2 years [1.0-1.7] (Table 5).  
Table 5 - Demographical and clinical characteristics of the cohort at the 2 visits. Data are mean 
±SD or median [interquartile range] 
 Visit 1 Visit 2 p 
Age (yr) 14.5 ±2.3 
[range: 10.1-20.1] 
16.0 ±2.3 
[range: 11.4-21.8] 
<0.001 
Duration of disease (yr) 5.5 
[3.4-9.0] 
7.1 
[4.9-10.2] 
<0.001 
BMI SDS 0.8 ±1.0 0.8 ±1.0 0.278 
A1c (%) 8.7 
[8.0-9.8] 
9.0 
[7.9-10.1] 
0.398 
TRAIL (pg/ml) 78.6 
[65.9-97.6] 
73.0 
[56.8-92.1] 
0.001 
sCD25 (pg/ml) 3183 
[2546-3903] 
2873 
[2263-3634] 
<0.001 
hs-CRP (mg/dl) 0.6 
[0.2-1.3] 
0.6 
[0.2-1.8] 
0.040 
C-peptide (pmol/l) 23.8 
[9.5-65.1] 
22.1 
[10.5-59.1] 
<0.001 
 
Log TRAIL levels were inversely correlated with age at bleed (p=1.05 × 10-7), 
duration of disease (p=6.56 × 10-6)  and seasonality (p=1.42 × 10-4) (with spring 
as the most associated and summer the least) (Table 6). A significant (p=0.001) 
decrease between visit 1 and visit 2 was detected for TRAIL (Table 5).  
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Table 6. Clinical and biochemical variables associated with Log TRAIL. Results are adjusted 
for repeated measure using GEE model. 
 
 
 B (95% CI) p value 
Age at bleed -0.021 (-0.028, -0.013) 1.05 × 10-7 
Duration of disease -0.012 (-0.018, -0.007) 6.56 × 10-6 
Seasonality  0.036 (0.017, 0.054) 1.42 × 10-4 
Age at diagnosis 0.002 (-0.003, 0.008) 0.463 
Log A1c 0.055 (-0.221, 0.331) 0.697 
BMI SDS 0.001 (-0.18, 0.021) 0.907 
Female Sex 0.036 (-0.004, 0.077) 0.076 
 
 
The reduction over time in C-peptide (used as marker of beta-cell function) was 
significant from visit 1 (median 23.8 pmol/l [9.5-65.1]) to visit 2 (median 22.1 
pmol/l [10.5-59.1]) (p<0.001) (Table 5). However, no association was found 
between Log TRAIL and Log C-peptide (β coefficient=0.015, p=0.472) (Table 
7) and the association between Δ TRAIL and Δ C-peptide did not reach 
statistical significance (β coefficient=0.024, p=0.068). 
 
 
Table 7. Independent associations between TRAIL and markers of beta cell function and 
immune and inflammatory markers. Each model was built separately and results are adjusted 
for seasonality, sex, BMI SDS, Log A1c, age at diagnosis and duration of T1D and repeated 
measure using GEE model. 
 
 
 B (95% CI) p value 
Model 1: β-cell function marker 
Log C-peptide -0.015 (-0.054, 0.025) 0.472 
 
Model 2: inflammation marker 
Log hs-CRP 0.014 (-0.033, 0.060) 0.557 
 
Model 3: immune system marker 
Log sCD25 0.231 (0.094, 0.368) 0.001 
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The inflammatory marker, hs-CRP, increased significantly (p=0.040) over time, 
from visit 1 (0.6 mg/dl [0.2-1.3]) to visit 2 (0.6 mg/dl [0.2-1.8]) (Table 5). However 
Log TRAIL was not associated with Log hs-CRP (β coefficient=-0.014, p=0.557) 
(Table 7) and the association between Δ TRAIL and Δ hs-CRP was not 
significant (β coefficient=0.068, p=0.857).  
The immune marker, sCD25, increased significantly (p<0.001) over time, from 
visit 1 (median 3183 pg/ml [2546-3903]) to visit 2 (median 2873 pg/ml [2263-
3634) (p<0.001) (Table 5).  
Log TRAIL was associated with Log sCD25 (β coefficient=0.222, p=3.55 × 10-4) 
(Table 7), even after adjustment for seasonality, sex, BMI SDS, Log A1c, age 
at diagnosis and duration of T1D (β coefficient=0.231, p=0.001); age at bleed 
was not included among adjustments because of collinearity with duration of 
disease (Spearman’s rho=0.3748, p<0.001).   
Also Δ TRAIL was associated with Δ sCD25 (β coefficient=0.348, p=3.02 × 10-5), 
even when adjusted for time between visits (β coefficient=0.349, p=3.08 × 10-5). 
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CHAPTER 5 
GENERAL DISCUSSION 
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1.	TRAIL	IN	TYPE	1	DIABETES	
 
In study I we measured TRAIL in a paediatric retrospective cohort, mainly 
including T1D patients and age-matched healthy control subjects154. Patients 
with T1D had a mean age of 9.3 years, with a mean age at diagnosis of 8.6 
years, including both recent onset and overt T1D (mean glycosylated 
haemoglobin [A1c] 10.9% – 95.6 mmol/mol). 
We have demonstrated that circulating levels of TRAIL were significantly 
decreased in patients with T1D (median 65.7 pg/ml) with respect to healthy 
control subjects (median 83.1 pg/ml) (Figure 9).  
These data are consistent with animal studies – which showed that systemic 
TRAIL blockade as well as knocking out TRAIL gene would increase both 
incidence and severity of autoimmune diabetes in genetically prone 
mice87,130,134 – and with a previous study on diabetic patients (50 patients with 
age up to 52 years, mean duration of disease 9 years, mean A1c 7%) in which 
TRAIL was significantly decreased in comparison with age- and sex-matched 
healthy controls144. In this study, the decoy/death receptor ratio was 
significantly increased in T cells of diabetic patients, probably leading to hyper-
activation of T cells and the consequent uprising of auto-reactive T cells which 
would act against susceptible self tissues. The increased expression of TRAIL-
R3 and TRAIL-R4 on T cells from diabetic patients might hinder these cells from 
inhibitory effects of TRAIL144.  
Lower levels of serum TRAIL in diabetic patients could be causative in 
pathogenesis of autoimmunity144: as cleavage of surface TRAIL from T-cells is 
considered to be one of the main sources of serum TRAIL159, this decrease 
may be the result of more stabilized surface TRAIL. Then a decrease in 
circulating TRAIL might lead to autoreactive T-cells uprising.  
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On the contrary, many studies have shown that soluble TRAIL causes cell 
cycle arrest and blocks cytokine production of autoreactive T cells121 and 
in this regard it is a prototype of autoimmune inflammation inhibitor117.  
We then confirmed reduced TRAIL levels in children with T1D compared to 
unaffected individuals. 
Moreover, in study III we reported the existence of a significant seasonal pattern 
of TRAIL, with the lower levels during summer and higher during spring, which 
may have some impact on the seasonal variation in the initial presentation of 
T1D158 and should be taken into account when planning further studies on 
TRAIL. 
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2.	TRAIL	AND	AUTOIMMUNITY	
 
Because of the well-documented immunoregulatory role of TRAIL in 
autoimmune diseases, in study I we investigated some indirect signs of 
autoimmunity in patients with T1D154. 
Firstly, circulating levels of TRAIL in healthy autoantibody-positive 
individuals (AutoAb POS/T1D NEG) (median 77 pg/ml), who have a higher 
risk of developing T1D than autoantibody-negative individuals do35,36, were not 
different with respect to healthy control subjects (median 83.1 pg/ml) 
(Figure 9). 
Secondly, T1D patients with islet-specific autoantibody (87% of total) did 
not differ from T1D autoantibody negative in terms of circulating TRAIL 
levels (Figure 11).  
Thirdly, TRAIL levels in relation to the presence of other concomitant 
autoimmune disorders (in 26.5% of the patients, mostly Hashimoto’s 
thyroiditis [68%], coeliac disease [21%]) in the T1D patients did not reveal any 
significant difference, both when considered together (Figure 12) or 
separately (for celiac disease and Hashimoto’s thyroiditis). 
These observations were against the hypothesis that a decrease in circulating 
TRAIL has some relationship with the severity of autoimmune reaction 
characterizing T1D.  
Two recent studies on other autoimmune diseases confirmed the incongruity of 
data regarding autoimmunity: 
- in patients with newly diagnosed Hashimoto’s thyroiditis (positive for 
both anti-thyroid peroxidase and anti-thyroglobulin antibodies) with 
subclinical hypothyroidism, circulating TRAIL levels were significantly 
lower than in controls (67.2  vs. 78.5 pg/ml)115  
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- in patients with coeliac disease (CD) at onset no significant differences 
were found in the circulating levels of TRAIL with regard to patients with 
either eosinophilic esophagitis or potential CD. Gluten-free diet did not 
significantly modify the levels of circulating TRAIL at 6 or 12 months. 
However, patients with CD associated with other auto-immune diseases 
(10%) showed significantly lower levels of TRAIL when compared with 
patients with CD alone (86 vs. 100 pg/ml).  
Because of this inconsistency, in study III we purposely aimed to assess the 
potential association between TRAIL and a measure of immune activation. In 
particular, we chose soluble CD25 (sCD25) (also known as IL-2 receptor α 
[IL-2RA]) which is an established marker of immune activation and 
inflammation, because of its known link with TRAIL134,160. 
IL-2RA subunit is essential for high-affinity binding of IL-2, and unlike the IL-
2RB subunit and the common cytokine receptor γ chain, which bind to other 
cytokines, the α subunit is unique to IL-2161. The IL-2/IL-2RA signalling pathway 
is essential for the regulation of immune responses. Rare IL-2RA mutations 
cause systemic autoimmune disease in humans162,163.  
Elevated sCD25 concentrations in adults are associated with activation of 
lymphocytes during autoimmune disease164–166, thus sCD25 has been used as 
a biomarker to help characterize disease progression, prognosis and 
treatment166–168. In a recent paper sCD25 was found to be increased in T1D 
patients and inversely associated with C-peptide, probably reflecting the 
adverse effects of an ongoing, actively autoimmune and inflammatory immune 
system on β-cell function in patients153.  
We then analysed TRAIL and sCD25 in a retrospective cohort study on 232 
young patients (mean age 14.5 years) with a long-standing T1D (median 
duration of disease 5.5 years) and a poor controlled diabetes (mean A1c 8.7% 
– 72 mmol/mol) and a significant association was found between TRAIL and 
sCD25.   
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The majority of these patients (n=219) had 2 available stored non-fasting serum 
samples collected (median of time interval between the 2 visits: 1.2 years), and 
a significant reduction in sCD25 was found over time, possibly reflecting a 
reduced immune activation in T1D, which is generally supported by the finding 
of reduced levels of autoantibodies decrease with duration of diabetes169,170. 
The association between TRAIL and CD25 was confirmed both as single values 
and as changes over time.  
IL-2 appears to be the dominant cytokine in reprogramming “helpless” CD8+ T 
cells to β-cell specific cytotoxic lymphocytes during antigenic restimulation, 
significantly (but not completely) decreasing the production of TRAIL160. The 
recovery of functional CD8+ T cell immunity by IL-2 is concomitant with 
induction of CD25 expression and down-regulation of TRAIL160. On the other 
hand, TRAIL inhibits in the NOD mouse the proliferation of diabetogenic T-cells 
by suppressing IL-2 production and cell cycle progression, and this inhibition 
can be rescued in the presence of exogenous IL-2134. 
The link found between TRAIL and CD25 across age and duration of T1D could 
therefore imply that the observed down-regulation of TRAIL reflects the 
active autoimmune inflammatory process mediated by IL-2, even years 
after the onset of diabetes. 
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3.	TRAIL	AT	THE	ONSET	OF	TYPE	1	DIBAETES	
 
In study I, evaluating the levels of circulating TRAIL in relation to the time from 
diagnosis, TRAIL values at “onset” (median 61.2 pg/ml) were significantly 
lower than the levels measured at later time points after diagnosis, both 
with respect to ‘‘≤1 year’’ (median 71.3 pg) and to ‘‘>1 year’’ after diagnosis 
(median 70.0 pg/ml)154 (Figure 13).  
 
Among T1D patients with blood taken at onset, TRAIL levels were 
significantly lower in patients with DKA (median 58.7 pg/ml) than in patients 
without DKA at diabetes onset (median 73.1 pg/ml) (Figure 14).  
Unfortunately, the first study just evaluated a retrospective cohort with no 
information about concurrent metabolic status at time of blood sampling.  
Hence study II was prospective on a cohort of pediatric subjects admitted for 
T1D onset or secondary DKA at the Emergency Department171. Similarly, in this 
cohort the lowest levels of TRAIL were measured in patients with DKA 
(median 47.9 pg/ml) with respect to patients without DKA (median 76.14 pg/ml), 
confirming the previous results. 
Analysis of TRAIL levels in relationship with all the clinical/metabolic 
parameters revealed a significant correlation only between TRAIL levels 
and HCO3, BE, pH and pCO2 (Table 3; Figure 17). No correlation was found 
between TRAIL levels and C-peptide, A1c, blood glucose or insulin daily 
requirement at discharge from the hospital. 
In all patients, we documented a significant and prompt increase of 
circulating TRAIL levels from admission (median 52.8 pg/ml) to the time of 
discharge (median 109.8 pg/ml) over a median time of 2.5 days (Figure 15).  
Since the lowest levels of TRAIL were documented in T1D patients with DKA 
at the onset, these data suggest a link between circulating TRAIL and the 
severity of the disease. The fact that TRAIL levels are lower in patients with 
DKA (at onset or secondary) and are correlated with metabolic parameters, 
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points to a possible association of TRAIL with the metabolic stress 
underlying T1D. 
These data are in agreement with recent studies performed on T2D, which 
showed that circulating levels of TRAIL were significantly decreased in newly 
diagnosed T2D patients when compared to controls, and increased after 6 
months of diabetic treatment172. 
The fact that both types of diabetes at diagnosis are characterized by low levels 
of circulating TRAIL suggests that also metabolic endangerment – other than 
autoimmunity – could be a preponderant cause for the decrease in the 
circulating levels of TRAIL. However, metabolic status cannot be the only cause 
for reduction in TRAIL levels: TRAIL persists lower than controls levels even a 
long time after treatment with insulin or metformin has been started and good 
metabolic status has been steadily reached. Moreover TRAIL is not related to 
A1c levels. 
Patients with DKA are supposed to have lower residual β-cell mass (1-30%)173, 
while in many patients levels of stimulated C-peptide at diagnosis are only 
partially reduced174,175. The improvement in C-peptide responses that have 
been identified in the first months after diagnosis in some individuals suggests 
that repair of the loss of β-cell function and/or mass may occur early in the 
course of the disease, either by halting the progression of autoimmune process 
or by renewing β-cells, and that TRAIL might be related to these changes176. 
However TRAIL seems not to be related to C-peptide, as an estimation of 
residual functional β-cell mass, although in study II subjects might have been 
too few to find a significant association and in study III data related to long-
standing T1D patients might have been biased by absent C-peptide secretion.  
A potential molecular mechanism that links metabolic state and circulating 
levels of TRAIL could be represented by CRP. In individuals with pre-diabetes 
(both type 1 and type 2) inflammatory processes might influence β-cell 
function and glycaemic control177. Indeed, it has been shown that CRP is 
elevated in children with newly diagnosed T1D and DKA crisis and that it likely 
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enhances inflammation process by modulating a variety of cytokines178. In 
children with moderate to severe DKA at T1D onset, the presence of increased 
levels of CRP (without the presence of infection) were reversed with insulin 
administration in 24 hours, indicating the anti-inflammatory role of insulin178. 
Likewise, it has been documented that TRAIL expression and release is down-
regulated by CRP. However no association was found between TRAIL and 
CRP in T1D in study III. Given that those data were related to patients with 
established T1D with variable duration of the disease instead of recently 
diagnosed ones, all these effects might have been lost after many years of 
disease, whereas they might be relevant in the early stage of disease. 
One more explanation could be an early and persistent microvascular 
damage in diabetes mellitus. As a matter of fact, in the study on T2D patients, 
TRAIL levels were positively associated with endothelial function evaluated with 
flow-mediated endothelium-dependent arterial dilatation (FMD)172. This finding 
has been replicated in a cohort of patients with subclinical hypothyroidism: 
circulating TRAIL levels were positively associated with endothelial function179, 
thus suggesting that TRAIL levels may be a protective marker of endothelial 
function180. 
Consistent with this findings, in patients with proliferative diabetic retinopathy 
soluble TRAIL levels measured in the conjunctival sac were significantly lower 
with respect to both patients without retinopathy  and patients with non-
proliferative diabetic retinopathy. A decreased production and/or release of 
TRAIL might then contribute to worsening proliferative diabetic retinopathy, 
possibly by reducing the degree of apoptosis in retinal endothelial cells181. 
Moreover, in mice TRAIL deficiency contributes to diabetic nephropathy with an 
increased extracellular matrix, mesangial expansion and mesangial cell 
proliferation in the glomeruli and disorganisation of tubular epithelium, with 
increased fibrosis182.  
Future longitudinal studies are needed to understand TRAIL modulation in T1D, 
particularly in relation with endothelial function (at onset and during follow-up) 
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and with microvascular complications (such as retinopathy, nephropathy and 
neuropathy). 
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4.	TRAIL	IN	LONG-LASTING	TYPE	1	DIABETES	
 
As already reported, in study I TRAIL levels increased with time. TRAIL 
values from 48 hours until 1 year after diagnosis (‘‘≤1 year’’) and thereafter (“>1 
year”) were significantly higher than values at onset (median 71.3 pg and 70.0 
pg/ml, respectively, vs 61.2 pg/ml). Nevertheless, also in patients analysed 
more than 1 year after onset TRAIL levels were still significantly lower 
with respect to healthy controls (median 83.1 pg/ml)154. 
Because of the retrospective nature of the study, there was no chance to 
sequentially evaluate modulation TRAIL levels in the same patients over time. 
In study II, by contrast, we could follow prospectively the same patients from 
the onset of T1D onwards. After a significant increase of circulating TRAIL 
levels during the first days of hospitalization, we documented a further 
significant increase from hospital discharge (median 109.8 pg/ml) to the 6-
month follow-up (median 147.3 pg/ml). TRAIL levels were then maintained 
without significant modulations in the subsequent time 
points/assessments up to 18 months171 (Figure 16). 
These data confirmed that the improvement in TRAIL could be seen soon after 
commencement of treatment (as already demonstrated in T2D)172. 
Nevertheless study III showed that in patients with long-standing T1D 
(median duration of disease 5.5 years), TRAIL levels significantly decreased 
from the first visit (median 78.6 pg/ml) to the second one (median 73.0 pg/ml), 
with a median time of 1.2 years between the two visits.  The observed reduction 
in TRAIL over time was independently associated with lowering of sCD25 
(independently from the age, duration of disease and seasonality). As already 
reported, this reduction in sCD25 might reflect a reduced immune activation 
occurring in T1D with duration of disease169,170. By contrast, no association was 
found between TRAIL and C-peptide or hsCRP in long-lasting T1D (Table 7). 
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For a subgroup of T1D patients in study I, for which we had insulin requirements 
at 3-month intervals up to 21 months of follow-up, we analysed the rank 
correlation between TRAIL levels at onset and daily insulin requirements up to 
21 months after onset. With the exception of the ‘‘3 months’’ time point, TRAIL 
levels at onset were significantly and negatively correlated at the insulin 
daily requirement (U/Kg/day) at all time analysed up to 21 months after 
discharge.  
The significant surge in TRAIL levels shortly after short-standing insulin 
treatment has been established in newly diagnosed T1D or in secondary DKA 
and the further significant increase in the following 6 months call to mind the 
increasing concentrations of circulating C-peptide and the lower insulin 
requirement that take place soon after clinical diagnosis (“honeymoon” 
period)52–56. Although no associations were found between TRAIL and C-
peptide in T1D at onset (in study II) or in long-standing disease (in study III), 
this could be due to scarcity of subject and exhausted β-cells, respectively. On 
the contrary the negative correlation between TRAIL and insulin requirement 
up to 21 months after onset would be in favour of an association between TRAIL 
and β-cells residual function. In this regard, TRAIL at onset may predict insulin 
requirement in the medium term and could be used as a predictive biomarker.  
Future longitudinal studies are needed to further investigate TRAIL levels in 
relation to β-cell function: the chance to use recombinant TRAIL to induce 
immune tolerance against residual β-cell, halt autoimmune destruction and 
preserve C-peptide make this line of research particularly interesting. 
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CONCLUSION AND PERSPECTIVES 
 
 
We showed for the first time the behaviour of circulating TRAIL in paediatric 
patients with T1D, both at onset and years after onset, in 3 different cohorts. 
While observations in patients with long-standing T1D strengthen the link 
between TRAIL and immune activation, in recent-onset patients TRAIL is 
strongly linked with metabolic status. Although preliminary experimental data 
suggested a potential beneficial effect of TRAIL on β-cell survival, we could not 
find any association between TRAIL and C-peptide. 
Future studies are needed to investigate the association of TRAIL with: 
- immune activation and general inflammation in children with recent onset of 
T1D;  
- residual β-cell mass at onset and throughout remission period; 
- immune activation, general inflammation and residual β-cell mass in children 
with T2D; 
- endothelial function and long-term complications in long-standing T1D. 
Whether Dulanermin (recombinant TRAIL) – which has shown a safety profile 
in several clinical studies – will have therapeutic perspective remains an open 
question, which requires additional preclinical studies. 
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